Tetracosactide ( DrugBank: Tetracosactide )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
83	アジソン病	2
113	筋ジストロフィー	4
145	ウエスト症候群	2
222	一次性ネフローゼ症候群	1

83. アジソン病

臨床試験数 : 20 / 薬物数 : 39 - (DrugBank : 13) / 標的遺伝子数 : 6 - 標的パスウェイ数 : 18

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2012-001682-33-GB (EUCTR)	06/09/2012	15/06/2012	Rescue of Addison’s disease 2	Combined Immunotherapy and Trophic Adrenocortical Stimulation in New Onset Autoimmune Addison’s Disease - Rescue of Addison’s disease 2 (RADS2)	Autoimmune Addison's disease: autoimmune primary adrenal insufficiency MedDRA version: 16.1;Level: PT;Classification code 10052381;Term: Primary adrenal insufficiency;System Organ Class: 10014698 - Endocrine disorders MedDRA version: 16.1;Level: LLT;Classification code 10001335;Term: Adrenal cortex insufficiency;Classification code 10001342;Term: Adrenal cortical hypofunction;System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Trade Name: Mabthera infusion Product Name: Mabthera Infusion Product Code: Rituximab Trade Name: Solu-Medrone Product Name: Solu-Medrone Product Code: Methylprednisolone Trade Name: Synacthen Depot Product Name: Synacthen Depot Product Code: Tetracosactide acetate	Newcastle upon Tyne Hospitals NHS Foundation Trust	NULL	Not Recruiting			Female: yes Male: yes	30	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom
2	NCT01371526 (ClinicalTrials.gov)	September 2010	9/3/2011	Revival of Stem Cells in Addison's Study	Revival of Autochthonous Adrenocortical Stem Cells in Autoimmune Addison's Disease	Adrenal Failure	Drug: depot tetracosactide	Newcastle University	NULL	Completed	16 Years	66 Years	Both	13	Phase 4	United Kingdom

113. 筋ジストロフィー

臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2017-004139-35-IT (EUCTR)	31/08/2018	17/06/2021	Clinical Trial in Male Subjects with Muscular Disease	A Multicenter, Randomized, Parallel Group, Double Blind, Multiple Dose, Placebo Controlled Study to Assess the Efficacy and Safety of MNK-1411 in Male Subjects 4 to 8 Years of Age With Duchenne Muscular Dystrophy - Clinical Trial in Male Subjects with Muscular Disease	Duchenne Muscular Distrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cosintropina acetato Product Code: [MNK-1411] INN or Proposed INN: TETRACOSACTIDE ESACETATO Other descriptive name: Cosyntropin acetate Trade Name: Synacthen Ampoules 250 mcg Product Name: Synacthen Ampoules 250 microgrammi Product Code: [Synacthen Ampoules 250 microgrammi] INN or Proposed INN: TETRACOSACTIDE	MALLINCKRODT ARD INC.	NULL	Authorised-recruitment may be ongoing or finished	Female: no Male: yes	132	Phase 2	Serbia;United States;Spain;Costa Rica;Ukraine;Ireland;Turkey;Israel;Russian Federation;United Kingdom;Italy;India;Mexico;Canada;Puerto Rico;Poland;Bulgaria
2	EUCTR2017-004139-35-BG (EUCTR)	28/08/2018	28/06/2018	Clinical Trial in Male Subjects with Muscular Disease	A Multicenter, Randomized, Parallel Group, Double Blind, Multiple Dose, Placebo Controlled Study to Assess the Efficacy and Safety of MNK-1411 in Male Subjects 4 to 8 Years of Age With Duchenne Muscular Dystrophy	Duchenne Muscular Distrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cosyntropin acetate Product Code: MNK-1411 INN or Proposed INN: TETRACOSACTIDE HEXAACETATE Other descriptive name: Cosyntropin acetate	Mallinckrodt ARD Inc.	NULL	Not Recruiting	Female: no Male: yes	132	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	Serbia;United States;Spain;Turkey;Chile;Israel;United Kingdom;Italy;Canada;Argentina;Belgium;Bulgaria;Germany;Netherlands
3	EUCTR2017-004139-35-BE (EUCTR)	18/06/2018	03/04/2018	Clinical Trial in Male Subjects with Muscular Disease	A Multicenter, Randomized, Parallel Group, Double Blind, Multiple Dose, Placebo Controlled Study to Assess the Efficacy and Safety of MNK-1411 in Male Subjects 4 to 8 Years of Age With Duchenne Muscular Dystrophy	Duchenne Muscular Distrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cosyntropin acetate Product Code: MNK-1411 INN or Proposed INN: TETRACOSACTIDE HEXAACETATE Other descriptive name: Cosyntropin acetate	Mallinckrodt ARD Inc.	NULL	Authorised-recruitment may be ongoing or finished	Female: no Male: yes	132	Phase 2	United States;Serbia;Spain;Turkey;Chile;Israel;United Kingdom;Italy;Canada;Argentina;Belgium;Germany;Netherlands
4	EUCTR2017-004139-35-ES (EUCTR)	12/06/2018	19/03/2018	Clinical Trial in Male Subjects with Muscular Disease	A Multicenter, Randomized, Parallel Group, Double Blind, Multiple Dose, Placebo Controlled Study to Assess the Efficacy and Safety of MNK-1411 in Male Subjects 4 to 8 Years of Age With Duchenne Muscular Dystrophy	Duchenne Muscular Distrophy MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cosyntropin acetate Product Code: MNK-1411 INN or Proposed INN: TETRACOSACTIDE HEXAACETATE Other descriptive name: Cosyntropin acetate	Mallinckrodt ARD Inc.	NULL	Not Recruiting	Female: no Male: yes	132	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United States;Serbia;Spain;Turkey;Chile;Israel;United Kingdom;Italy;Canada;Argentina;Belgium;Bulgaria;Germany;Netherlands

145. ウエスト症候群

臨床試験数 : 43 / 薬物数 : 52 - (DrugBank : 15) / 標的遺伝子数 : 28 - 標的パスウェイ数 : 26

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2006-000788-27-DE (EUCTR)	23/09/2010	11/06/2010	International Collaborative Study of a type of epilepsy called Infantile Spasms	International Collaborative Infantile Spasms Study (ICISS) - ICISS	Infantile spasms are a rare severe form of epilepsy affecting approx 1 in 2,250 infants, usually under the age of 1 year. Affected infants have a very abnormal EEG and a poor prognosis for subsequent epilepsy and neuro-development. There is a high risk of underlying neurological disease that independently causes delayed development and other seizure disorders. There is a high risk of a poor outcome even when there is no other detectable underlying neurological disorder.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: SABRIL INN or Proposed INN: Vigabatrin Trade Name: Synacthen Depot INN or Proposed INN: Tetracosactide Acetate Trade Name: Decortin H INN or Proposed INN: Prednisolone	Royal United Hospital Bath NHS Trust	NULL	Not Recruiting			Female: yes Male: yes	410	Phase 4	Australia;Germany;United Kingdom;Switzerland;New Zealand
2	EUCTR2006-000788-27-GB (EUCTR)	20/04/2006	06/03/2006	International Collaborative Infantile Spasms Study (ICISS) - ICISS	International Collaborative Infantile Spasms Study (ICISS) - ICISS	Infantile spasms are a rare severe form of epilepsy affecting approx 1 in 2,250 infants, usually under the age of 1 year. Affected infants have a very abnormal EEG and a poor prognosis for subsequent epilepsy and neuro-development. There is a high risk of underlying neurological disease that independently causes delayed development and other seizure disorders. There is a high risk of a poor outcome even when there is no other detectable underlying neurological disorder.	Trade Name: SABRIL SACHETS INN or Proposed INN: Vigabatrin Trade Name: SYNACTHEN DEPOT INN or Proposed INN: Tetracosactide Acetate Trade Name: SOLUBLE PREDNISOLONE TABLETS INN or Proposed INN: Prednisolone	Royal United Hospital Bath NHS Trust	NULL	Not Recruiting			Female: yes Male: yes	410	Phase 4	Germany;United Kingdom

222. 一次性ネフローゼ症候群

臨床試験数 : 310 / 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00694863 (ClinicalTrials.gov)	July 2008	9/6/2008	Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy	Treatment With Synthetic Adrenocorticotropic Hormone (ACTH) in Patients With Membranous Nephropathy and High Risk for Renal Failure. A Pilot Study	Idiopathic Membranous Nephropathy	Drug: tetracosactide hexacetaat	Radboud University	Dutch Kidney Foundation	Completed	18 Years	95 Years	Both	20	Phase 2	Netherlands

先頭へ